Occupational Therapy Is a Vital Member of the Interprofessional <scp>Team‐Based</scp> Approach for the Management of Rheumatoid Arthritis: Applying the 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

Baker, Nancy A.; Carandang, Kristine; Dodge, Carole; Poole, Janet L.

doi:10.1002/acr.25122

Cited by 3 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The American College of Rheumatology, European League Against Rheumatism, and international guidelines do not mention cannabis, cannabis-derived products, and synthetic cannabinoids for the treatment of patients with RA. [47][48][49] On the other hand, the College of Family Physicians of Canada recommends against the use of medical cannabinoids for pain due to rheumatologic conditions including RA, 50,51 whereas the Canadian Rheumatology Association position statement on medical cannabis use in rheumatic disease recognizes the lack of evidence for its use in rheumatology patients, but encourages patients to discuss benefits and risks with their physician. 52 The major part of the included systematic reviews was not specifically focused on patients with RA (e.g., noncancer chronic pain, rheumatic diseases), but most of those that made a declaration particularly for our population agreed that the evidence is insufficient to draw a conclusion.…”

Section: Discussionmentioning

confidence: 99%

Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence

Schulze

Durán²,

Bravo-Jeria

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

Background: Symptom management in rheumatoid arthritis (RA) remains a complex challenge. Widespread use of cannabis-based medicines for a myriad of symptoms has fostered rheumatology patients' interest. However, their safety and efficacy in RA remain unclear.Objective: The aim of this study was to perform a structured summary of the body of evidence in order to determine whether cannabis, cannabis-derived products, and synthetic cannabinoids are an effective treatment for rheumatoid arthritis.Methods: An electronic search in Epistemonikos database was performed to identify systematic reviews and their primary studies that addressed our clinical question. The body of evidence was collected in a pivot table in Epistemonikos. Information and data from the primary studies were extracted from the identified reviews. Finally, extracted data were reanalyzed, and a summary of findings table was generated using the Grading of Recommendations Assessment, Development and Evaluation approach.Results: Twenty-six systematic reviews were identified which included in total only 1 randomized trial assessing our clinical question.Conclusions: Cannabis, cannabis-derived products and synthetic cannabinoids may slightly reduce disease activity in patients with RA. Its use may result in little to no difference in pain reduction and may slightly increase nervous system adverse events. The evidence is very uncertain about the effect of cannabis, cannabis-derived products, and synthetic cannabinoids on serious adverse events risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence

Schulze

Durán²,

Bravo-Jeria

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…The focus on problem‐solving and application of strategies equips people with SSc with skills to handle new challenges or redesign expectations yet continue to participate in valued activities and roles. 26 , 27 , 28 A logic model was developed to identify the main components of the program and to guide evaluation of FAME‐iSS (Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Increased Confidence and Deeper Understanding of Fatigue Following Participation in Fatigue Education and Management Education in Systemic Sclerosis: A Mixed Methods Evaluation of a Virtual Intervention

Poole,

Carandang,

Connolly

2024

ACR Open Rheumatology

Self Cite

View full text Add to dashboard Cite

ObjectiveNo fatigue‐specific programs exist for people with systemic sclerosis (SSc) despite the burden of fatigue and negative impact on daily activities. This study used a convergent parallel mixed methods design to evaluate the impact of an adapted virtual intervention, Fatigue and Activity Management Education in Systemic Sclerosis (FAME‐iSS), in the United States.MethodsEighteen people with SSc participated in three separate six‐week FAME‐iSS programs. Participants completed the modified Fatigue Impact Scale (m‐FIS), the Self‐Efficacy for Performing Energy Conservation Strategies Assessment (SEPESCA), the Patient‐Reported Outcomes Measurement Information System (PROMIS) Self‐Efficacy for Managing Symptoms, and the Hospital Anxiety and Depression Scale (HADS) before, immediately after, and three months post intervention. Data were analyzed using descriptive and nonparametric inferential statistics. Participants’ perceptions of the program and their use of fatigue management strategies were qualitatively analyzed using content analysis.ResultsEighty‐nine percent of participants were women with a mean ± SD age of 52.0 ± 11.6 years and a mean ± SD disease duration of 13.7 ± 14.5 years, and more than 70% had a college degree. Significant improvements were observed for self‐efficacy on the PROMIS Self‐Efficacy for Managing Symptoms (P = 0.002) and SEPESCA (P = 0.016) immediately post intervention, which continued to significantly improve up to the three‐month follow‐up (P = 0.006 and 0.035, respectively). Significant improvements were also observed for the m‐FIS between baseline and the three‐month follow‐up (P = 0.029). Participants reported a deeper understanding of fatigue and that they liked sharing strategies and experiences with each other along with the facilitator, citing that “there was a power in our group because we had a common condition.”ConclusionFAME‐iSS resulted in improvements in the impact of fatigue and self‐efficacy for managing symptoms and performing energy conservation strategies. Feedback was positive, and the virtual format allowed for greater accessibility and sharing of strategies.

show abstract

A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management

Conran,

Kolfenbach,

Kuhn

et al. 2023

Curr Rheumatol Rep

View full text Add to dashboard Cite

Occupational Therapy Is a Vital Member of the Interprofessional Team‐Based Approach for the Management of Rheumatoid Arthritis: Applying the 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

Cited by 3 publications

References 49 publications

Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence

Are Cannabis, Cannabis-Derived Products, and Synthetic Cannabinoids a Therapeutic Tool for Rheumatoid Arthritis? A Friendly Summary of the Body of Evidence

Increased Confidence and Deeper Understanding of Fatigue Following Participation in Fatigue Education and Management Education in Systemic Sclerosis: A Mixed Methods Evaluation of a Virtual Intervention

A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management

Contact Info

Product

Resources

About